Clene Inc. (CLNN): Nasdaq/NYSE listing notice — Clene receives Nasdaq deficiency notice for bid price below $1.00

Clene Inc.

Nasdaq notified Clene on May 31, 2023 that common stock failed Minimum Bid Price Requirement for 30 consecutive business days.
Company has 180 calendar days, until November 27, 2023, to regain compliance by closing at $1.00 or more for 10 consecutive business days.
If non-compliant by deadline, Clene may qualify for a second 180-day period if it meets other listing standards and intends to cure via reverse stock split.
Clene will monitor bid price and consider options but cannot assure compliance; stock continues trading under symbol CLNN.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Clene Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 31, 2023, Clene Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing in the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “CLNN.” In accord

View on SEC.gov

Browse all listing & compliance notices →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-016474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.